Literature DB >> 63265

Clinical correlations and significance of orceinpositivity in chronic active hepatitis and primary biliary cirrhosis.

M P Salaspuro, P Sipponen, E Ikkala, L Kolho, H M Makkonen, T A Miettinen, J A Räsänen, M Siurala.   

Abstract

Clinical, biochemical and immunological variables were analyzed in 30 patients with orcein-negative (ON) chronic active hepatitis (CAH), 4 patients with ON primary biliary cirrhosis (PBC), 8 patients with orcein-positive (OP; intracellular copper-binding protein seen histologically in liver biopsy specimens) CAH and 15 patients with OP-PBC. A marked elevation of serum bile acids, alkaline phosphatase, leusine aminopeptidase, gammaglutamyl transpeptidase and cholesterol concentrations, and highly pathological BSP Tm values were characteristic for OP-cases. In addition the faecal fat level was increased and bile acids decreased in OP-cases. Serum levels of IgG or IgM and the occurrence of smooth muscle, mitochondrial or glomerular antibodies were identical in ON- and OP-CAH as well as also in ON- and OP-PBC. 49 patients were treated with a combination of prednisone and azathioprine from 4 to 72 months (mean 22). 26 patients with ON-CAH responded biochemically and morphologically to the treatment. No treatment failures were found in ON-CAH. In contrast treatment failure was confirmed in every treated OP-PBC or OP-CAH. The results suggest that orcein-positivity indicates a poor response to prednisone-azathioprine treatment of CAH.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 63265

Source DB:  PubMed          Journal:  Ann Clin Res        ISSN: 0003-4762


  10 in total

1.  The problem of histologic evaluation of primary biliary cirrhosis.

Authors:  H Popper
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1978-08-22

2.  Demonstration of an intracellular copper-binding protein by orcein staining in long-standing cholestatic liver diseases.

Authors:  M Salaspuro; P Sipponen
Journal:  Gut       Date:  1976-10       Impact factor: 23.059

3.  Enzymes of collagen synthesis and type III procollagen aminopropeptide in the evaluation of D-penicillamine and medroxyprogesterone treatments of primary biliary cirrhosis.

Authors:  E R Savolainen; T A Miettinen; P Pikkarainen; M P Salaspuro; K I Kivirikko
Journal:  Gut       Date:  1983-02       Impact factor: 23.059

4.  Different types of smooth muscle antibodies in chronic active hepatitis and primary biliary cirrhosis: their diagnostic and prognostic significance.

Authors:  P Kurki; A Miettinen; E Linder; P Pikkarainen; M Vuoristo; M P Salaspuro
Journal:  Gut       Date:  1980-10       Impact factor: 23.059

Review 5.  Clinical, histologic, and immunopathologic features of primary biliary cirrhosis.

Authors:  H Popper; F Paronetto
Journal:  Springer Semin Immunopathol       Date:  1980-12

6.  Biliary lipids, faecal steroids, and liver function in patients with chronic active hepatitis and primary biliary cirrhosis: significance of hepatic orcein-stained complexes.

Authors:  Y A Kesäniemi; T A Miettinen; M P Salaspuro
Journal:  Gut       Date:  1981-07       Impact factor: 23.059

7.  Endotoxin and liver diseases. High titres of enterobacterial common antigen antibodies in patients with alcoholic cirrhosis.

Authors:  U Turunen; M Malkamäki; V V Valtonen; U Larinkaŕi; P Pikkarainen; M P Salaspuro; P H Mäkelä
Journal:  Gut       Date:  1981-10       Impact factor: 23.059

8.  Hepatic copper in primary biliary cirrhosis: biliary excretion and response to penicillamine treatment.

Authors:  M P Salaspuro; P Pikkarainen; P Sipponen; E Vuori; T A Miettinen
Journal:  Gut       Date:  1981-11       Impact factor: 23.059

9.  Biliary lipid secretion in chronic cholestatic liver disease.

Authors:  Y A Kesäniemi; M P Salaspuro; M Vuoristo; T A Miettinen
Journal:  Gut       Date:  1982-11       Impact factor: 23.059

Review 10.  Current Trends of Essential Trace Elements in Patients with Chronic Liver Diseases.

Authors:  Takashi Himoto; Tsutomu Masaki
Journal:  Nutrients       Date:  2020-07-14       Impact factor: 5.717

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.